참고문헌
- Ali I, M Ali K, Mehmet K, et al (2012). Prognostic factors for second-line treatment of advanced Non-small-cell lung cancer: retrospective analysis at a single institution. Asian Pac J Cancer Prev, 13, 1281-4. https://doi.org/10.7314/APJCP.2012.13.4.1281
- Ardizzoni A, Tiseo M, Boni L, et al (2012). Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer: results of the GOIRC 02-2006 randomized phase II study and pooled analysis with the NVALT7 trial. J Clin Oncol, 30, 4501-7. https://doi.org/10.1200/JCO.2012.43.6758
- Caponi S, Vasile E, Ginocchi L, et al (2010). Second-line treatment for non-small-cell lung cancer: one size does not fit all. Clinical Lung Cancer, 11, 320-7. https://doi.org/10.3816/CLC.2010.n.040
- de Marinis F, Ricciardi S (2011). Second-line treatment options in advanced non-small cell lung cancer. Eur J Cancer, 47, 258-71.
- Di Maio M, Krzakowski M, Fougeray R, Kowalski DM, Gridelli C (2012). Prognostic score for second-line chemotherapy of advanced non-small-cell lung cancer: external validation in a phase III trial comparing vinflunine with docetaxel. Lung Cancer, 77, 116-20. https://doi.org/10.1016/j.lungcan.2012.01.013
- Favaretto A, Pasello G, Magro C, Schettino C, Gridelli C (2009). Second and third line treatment in non-small cell lung cancer. Crit Rev Oncol Hematol, 71, 117-26. https://doi.org/10.1016/j.critrevonc.2009.01.009
- Gridelli C, de Marinis F, Cappuzzo F, et al (2014). Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. Clin Lung Cancer, 15, 173-81. https://doi.org/10.1016/j.cllc.2013.12.002
- Gao G, Ren S, Li A, et al (2012). Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: A meta-analysis from six phase III randomized controlled trials. Int J Cancer, 131, 822-9. https://doi.org/10.1002/ijc.27396
- Greillier L, Barlesi F (2012). Second-line treatment of metastatic non-small cell lung carcinoma: What are the options today? What are the perspectives for tomorrow?. Rev Mal Respir, 29, 4-6 (in French). https://doi.org/10.1016/j.rmr.2011.12.006
- Gomez P, Yorke R, Ayala AG, Ro JY (2012). Solid-pseudopapillary neoplasm of pancreas with long delayed liver metastasis. Ann Diagn Pathol, 16, 380-4. https://doi.org/10.1016/j.anndiagpath.2011.02.008
- Hanna N, Shepherd FA, Fossella FV, et al (2004). Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol, 22, 1589-97. https://doi.org/10.1200/JCO.2004.08.163
- Ishizuka M, Kita J, Shimoda M et al (2012). Impact of grading of liver metastasis on postoperative outcome in patients with liver metastases from colorectal cancer. Hepatogastroenterology, 59, 54-8.
- Lal R, Enting D, Kristeleit H. Systemic treatment of non-smallcell lung cancer (2011). Eur J Cancer, 47, 375-7. https://doi.org/10.1016/j.ejca.2010.09.043
- Moro-Sibilot D, Nishino M, Jackman DM, Hatabu H, et al (2010). New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy. AJR, 195, 221-8. https://doi.org/10.2214/AJR.09.3928
- Natukula K, Jamil K, Pingali UR, et al (2013). Survival analysis in advanced non small cell lung cancer treated with platinum based chemotherapy in combination with paclitaxel, gemcitabine and etoposide. Asian Pac J Cancer Prev, 14, 4661-6. https://doi.org/10.7314/APJCP.2013.14.8.4661
- Pao W, Chmielecki J. Rational (2010). Biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nature Reviews Cancer, 10, 760-74. https://doi.org/10.1038/nrc2947
- Qi WX, Shen Z, Lin F et al (2012). Comparison of the efficacy and safety of EGFR tyrosine kinase inhibitor monotherapy with standard second-line chemotherapy in previously treated advanced non-small cell lung cancer: a systematic revies and meta-analysis. Asian Pac J Cancer Prev, 13, 5177-82. https://doi.org/10.7314/APJCP.2012.13.10.5177
- Ramalingam SS, Owonikoko TK, Khuri FR (2011). Lung cancer: New biological insights and recent therapeutic advances. CA Cancer J Clin, 61, 91-112. https://doi.org/10.3322/caac.20102
- Ren S, Kuang P, Zheng L, et al (2012). Analysis of driver mutations in female non-smoker Asian patients with pulmonary adenocarcinoma. Cell Biochem Biophys, 64, 155-60. https://doi.org/10.1007/s12013-012-9384-8
- Ren S, Chen X, Kuang P, et al (2012). Association of EGFR mutation or ALK rearrangement with expression of DNA repair and synthesis genes in never-smoker women with pulmonary adenocarcinoma. Cancer, 118, 5588-94. https://doi.org/10.1002/cncr.27603
- Sun JM, Oh DY, Lee SH, et al (2010). The relationship between response to previous systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non-small cell lung cancer. Lung Cancer, 68, 427-32. https://doi.org/10.1016/j.lungcan.2009.07.013
- Tadashi Maeda, Hiroshi U, Masahiro T, et al (2000). Prognostic factors in advanced non-small cell lung cancer: Elevated serum levels of neuron specific enolase indicate poor prognosis. Jpn J Clin Oncol, 30, 534-41. https://doi.org/10.1093/jjco/hyd139
- Vergnenegre A, Corre R, Berard H, et al (2011). Costeffectiveness of second-line chemotherapy for non-small cell lung cancer: an economic, randomized, prospective, multicenter phase III trial comparing docetaxel and pemetrexed: the GFPC 05-06 study. J Thoracic Oncol, 6, 161-8. https://doi.org/10.1097/JTO.0b013e318200f4c1
- Vergnenegre A, Smit EF, et al (2010). Second-line therapy for NSCLC in clinical practice: baseline results of the European SELECTTION observational study. Curr Med Res Opin, 26, 2661-72. https://doi.org/10.1185/03007995.2010.525489
- Wu M, Zhao J, Song SW, et al (2010). EGFR mutations are associated with prognosis but not with the response to front line chemotherapy in the Chinese patients with advanced non-small cell lung cancer. Lung Cancer, 67, 343-7. https://doi.org/10.1016/j.lungcan.2009.04.011
- Weiss GJ, Rosell R, Fossella F, et al (2007). The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer. Ann Oncol, 18, 453-60.
- Zhou C, Wu Y-L, Chen G, et al (2011). Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, openlabel, randomised, phase 3 study. Lancet Oncol, 12, 735-42. https://doi.org/10.1016/S1470-2045(11)70184-X
- Zietemann V, Duell T (2011). Prevalence and effectiveness of first-, second-, and third-line systemic therapy in a cohort of unselected patients with advanced non-small cell lung cancer. Lung Cancer, 73, 70-7. https://doi.org/10.1016/j.lungcan.2010.10.017
- Zabaleta J, Aguinagalde B, Fuentes MG, et al (2011). Survival after lung metastasectomy for colorectal cancer: Importance of previous liver metastasis as a prognostic factor. Eur J Surg Oncol, 37, 786-90. https://doi.org/10.1016/j.ejso.2011.05.014
피인용 문헌
- Current Drugs and Drug Targets in Non-Small Cell Lung Cancer: Limitations and Opportunities vol.16, pp.10, 2015, https://doi.org/10.7314/APJCP.2015.16.10.4147
- Thyroid Transcription Factor-1 Expression in Advanced Non-Small Cell Lung Cancer: Impact on Survival Outcome vol.16, pp.7, 2015, https://doi.org/10.7314/APJCP.2015.16.7.2987
- Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity? pp.1744-8301, 2019, https://doi.org/10.2217/fon-2018-0948